...antidepressant Zoloft at $302.8 million and Amgen's injectable anemia drug Epogen at $288.5 million. Others were: Glaxo-Wellcome PLC's ulcer drug Zantac at $252.3 million, SmithKline Beecham PLC's antidepressant Paxil at $242.8 million...

...company. In an executive reshuffling, Robert A. Ingram was named chief executive of London-based parent company Glaxo Wellcome PLC. He will continue to head the U.S. operation with expanded authority as well.

...discussed merging with British drug maker SmithKline Beecham PLC. But SmithKline backed out in favor of talks with Glaxo Wellcome PLC, which were later aborted. In October, American Home and Monsanto called off their merger talks after leadership...

...Orbofiban, once it comes on line in two years, Mr. DeFer said. Other companies, including Merck & Co. and Glaxo Wellcome PLC, are working on similar arthritis drugs collectively known as "COX-2 blockers" for their ability to block a...

...spokesman in New York declined to comment on whether the case is linked to unusual price drops late Friday in shares of Glaxo Wellcome Plc and SmithKline Beecham Plc that raised the specter of market manipulation. Glaxo Wellcome's share price fell...

...spokesman in New York declined to comment on whether the case is linked to unusual price drops late Friday in shares of Glaxo Wellcome Plc and SmithKline Beecham Plc that raised the specter of market manipulation. Glaxo Wellcome's share price fell...

LONDON -- British pharmaceutical heavyweights Glaxo Wellcome PLC and SmithKline Beecham PLC reached agreement to merge into the world's largest drugmaker, the companies announced Monday. The...

British drugmakers again talk merger LONDON -- British pharmaceutical heavyweights Glaxo Wellcome PLC and SmithKline Beecham PLC said Friday that they've resumed merger talks. If successful, a union between them would create...

...Street, an expected wave of drug mergers suddenly appeared farther off Tuesday after SmithKline Beecham PLC and Glaxo Wellcome PLC scuttled merger talks. Drug stocks tumbled after the British drug makers terminated negotiations that would have...

NEW YORK -- The principle behind SmithKline Beecham PLC's merger talks with Glaxo Wellcome PLC is the same one that has Wall Street forecasting an orgy of drug unions: Bigger is better. The more money the combined drug maker...